A performance evaluation of 90Y dose-calibrator measurements in nuclear pharmacies and clinics in the United States.
A blind performance test was conducted to evaluate dose-calibrator measurements at nuclear pharmacies in the United States (US). Two test-sample geometries were chosen to represent those used for measurements of 90Y-ibritumomab tiuxetan (ZEVALIN). The radioactivity concentration of test-samples was verified by the US National Institute of Standards and Technology. Forty-five results were reported by 10 participants. Eighty percent of reported values were within the US Pharmacopoeia content standard (+/-10%) for 90Y-ZEVALIN. All results were within US Nuclear Regulatory Commission conformance limits (+/-20%) for defining therapeutic misadministrations.
Schultz
Michael K
MK
The National Institute of Standards and Technology, Nuclear Medicine Standards Program, 100 Bureau Drive, MS 8462, Gaithersburg, MD 20899, USA. michael-schultz@uiowa.edu
Cessna
Jeffrey T
JT
Anderson
Tamara L
TL
Ponto
James A
JA
Petry
Neil
N
Kowalsky
Richard J
RJ
Palmer
Matthew R
MR
Beinlich
Uwe F
UF
Baker
William
W
Hinkle
George H
GH
Hung
Joseph C
JC
Quinton
Timothy
T
Rice
Peter A
PA
Divgi
Chaitanya
C
Norenberg
Jeffrey P
JP
D000554:Ambulatory Care Facilities / Q000592:standards; D000911:Antibodies, Monoclonal / Q000032:analysis* / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000532:radiotherapy; D009683:Nuclear Medicine / Q000592:standards; D010594:Pharmacies / Q000592:standards; D010865:Pilot Projects; D011786:Quality Control; D016499:Radioimmunotherapy; D011874:Radiometry / Q000379:methods / Q000592:standards; D019275:Radiopharmaceuticals / Q000032:analysis* / Q000592:standards / Q000627:therapeutic use; D011879:Radiotherapy Dosage; D012015:Reference Standards; D014481:United States; D015021:Yttrium Radioisotopes / Q000032:analysis* / Q000592:standards / Q000627:therapeutic use
D000911:Antibodies, Monoclonal; D019275:Radiopharmaceuticals; D015021:Yttrium Radioisotopes; C422802:ibritumomab tiuxetan